Is it acceptable to validate at a scale less than that of the commercial process (e.g., 10%)?

The 10% rule originated from FDA’s Generic Drug Branch for purposes of submitting
bioavailability and dissolution data for solid oral dosage forms. It does not apply to API and Q7A
does not specifically address scale-up.